Brief: Carisma Therapeutics Announces First Patient Dosed In Phase 1 Study Of CT-0508 With KEYTRUDA
28/06/2023 14:30
June 28 (Reuters) - Carisma Therapeutics Inc CARM.O :
* CARISMA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1
STUDY OF CT-0508 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)
IN PATIENTS WITH HER2 OVEREXPRESSING SOLID TUMORS
Source text for Eikon: ID:nPn6rsXfpa
Further company coverage: CARM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary